首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3369674篇
  免费   245902篇
  国内免费   8410篇
耳鼻咽喉   45398篇
儿科学   111028篇
妇产科学   94264篇
基础医学   479628篇
口腔科学   93982篇
临床医学   311001篇
内科学   658594篇
皮肤病学   79203篇
神经病学   276393篇
特种医学   128996篇
外国民族医学   965篇
外科学   496470篇
综合类   69103篇
现状与发展   7篇
一般理论   1451篇
预防医学   266119篇
眼科学   76185篇
药学   246256篇
  12篇
中国医学   6465篇
肿瘤学   182466篇
  2019年   26502篇
  2018年   36864篇
  2017年   28400篇
  2016年   32484篇
  2015年   36890篇
  2014年   50826篇
  2013年   77100篇
  2012年   102537篇
  2011年   108792篇
  2010年   65105篇
  2009年   62606篇
  2008年   102143篇
  2007年   108678篇
  2006年   109888篇
  2005年   106025篇
  2004年   102021篇
  2003年   98319篇
  2002年   95017篇
  2001年   156414篇
  2000年   160103篇
  1999年   135220篇
  1998年   39228篇
  1997年   35014篇
  1996年   35461篇
  1995年   34115篇
  1994年   31462篇
  1993年   29515篇
  1992年   106344篇
  1991年   103210篇
  1990年   100011篇
  1989年   96553篇
  1988年   89038篇
  1987年   87268篇
  1986年   82278篇
  1985年   78418篇
  1984年   58997篇
  1983年   50331篇
  1982年   30023篇
  1981年   26986篇
  1979年   53107篇
  1978年   38029篇
  1977年   32256篇
  1976年   29843篇
  1975年   31956篇
  1974年   38070篇
  1973年   36730篇
  1972年   34574篇
  1971年   32128篇
  1970年   29906篇
  1969年   28539篇
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
61.
62.
Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement.

Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED).

Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.  相似文献   

63.
64.
65.
Academic output is just one aspect of a successful career as a plastic surgeon. However, for those with a strong interest in academia, the academic output of a department will likely be a key factor when deciding how to rank jobs. The aim of this study was to quantify and rank the academic output of plastic surgery units across the UK and Ireland. The Institute for Scientific Information (ISI) Web of Science Bibliometric analysis tool was used to collate cumulative (1950–2016), 10 year (2006–2016) and 3 years (2013–2015) research output data for plastic surgery units in the UK and Ireland. Sixty-six plastic surgery units were identified. Departments were ranked for each time period according to the number of papers produced, number of citations (Nc) and h-index (a measure of the impact of scientific output). The top 3 departments for number of papers in the last 10 years were The Royal Free Hospital, London (226) Broomfield Hospital, Chelmsford (218), and Morriston Hospital and Swansea (188). The top 3 for h-number were The Royal Free Hospital (21) Wythenshawe Hospital, Manchester (18) and Morriston Hospital (17). Academic output varies across plastic surgery units in the UK and Ireland. A number of departments have consistently maintained high academic outputs across the years and will be of interest to surgeons hoping to pursue a career in academia.  相似文献   
66.
67.
68.
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was...  相似文献   
69.

Purpose

Endovascular treatment with mechanical thrombectomy devices demonstrated high recanalization rates but functional outcome did not correlate with high rates of recanalization obtained. Patient selection prior to the endovascular treatment is very important in the final outcome of the patient. The primary aim of our study was to evaluate the prognostic value of posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) and Pons-Midbrain Index (PMI) scores in patients with Basilar Artery Occlusion (BAO) treated with successful angiographic recanalization after mechanical thrombectomy.

Methods

Retrospective single-center study including 18 patients between 2008 and 2013 who had acute basilar artery occlusion managed with endovascular treatment within 24 hours from symptoms onset and with successful angiographic recanalization. The patients were initially classified into two groups according to clinical outcome and mortality at 90 days. For analysis we also divided patients into groups based on pc-ASPECTS (≥8vs.< 8) and PMI (≥3vs.< 3) on non-contrast CT (NCCT) and CT Angiography Source Images (CTASI). Imaging data were correlated to clinical outcome and mortality rate.

Results

CTASI pc-ASPECTS, dichotomized at < 8 versus≥8, was associated with a favorable outcome (RR: 2.6; 95% CI: 1.3-5.2) and a reduced risk of death (RR: 6.5: 95% CI: 7.8-23.3). All patients that survived and were functionally independent had pc-ASPECTS score≥8. None of the 5 patients with CTASI pc-ASPECTS score less than 8 survived.

Conclusion

PC-ASPECTS on CTASI is helpful for predicting functional outcome after BAO recanalization with endovascular treatment. These results should be validated in a randomized controlled trial in order to decide whether or not to treat a patient with BAO.  相似文献   
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号